Objective To study the effect of dipsacus on the expression of β-amyloid in parietal cortex and hippocampus of Alzheimer's disease model rats.Methods A total of 40 rats were randomly divided into control group,model group,dipsacus group and vitamin E group (n=10,each)General situation of rats was observed after 42 days of dipsacus treatment.The ability of learning and memory in rats was tested by Morris water maze.The content of β-amyloid in parietal cortex and hippocampus of each group rats were measured using double antibody sandwich method.Results Model group compared with control group showed that general conditions deteriorated markedly;escaping delitescence was prolonged significantly(P＜0.01) ; the activity time on the former platform quadrant reduced significantly (t=4.6261,P=0.0002) ; the number of crossing the former platform reduced significantly (t=6.5335,P=0.0000) ; the content of Aβ in parietal cortex and hippocampus increased significantly (t=4.2812,P=0.0004) (t=5.2499,P=0.0001).Dipsacus group and vitamin E group compared with model group showed that general condition improved significantly;escape latency was shortened significantly (P＜ 0.01); the activity time on the former platform quadrant increased significantly [(45.76±12.15) s,(48.70±10.25) s and (30.20±10.48) s (t=3.0666,3.9908,P=0.0066,0.0009)]; the number of crossing the former platform increased significantly [(3.02±1.19) t/2min,(3.56±0.85) t/2min and (1.43 ± 1.24) t/2min (t=2.9256,4.4804,P=0.0090,0.0003)]; the content of Aβ in parietal cortex and hippocampus reduced significantly in parietal cortex [(280.37-51.40) pg/g,(263.14 ± 45.52) pg/g versus (337.46 ±70.51) pg/g (t=2.1164,2.8003,P=0.0485,0.0118)],in hippocampus [(295.60±67.58)pg/g,(274.38±57.56)pg/g versus (388.26±83.72)pg/g(t=2.9256,4.4804,P=0.0090,0.0003)].Conclusions Dipsacus can reduce expression of Aβ in brain areas related to general intelligence that may have anti-Alzheimer's disease action.The active ingredients of dipsacus may be natural vitamin E.

AIM: To observe the clinical effect of Complound Rich Selenium Refined Konjal Meal Capsule on hyperlipemia. METHODS: The patients with hyperlipemia were randomly divided into two groups. The treatment group was given (0.5) g of Compound Rich Selenium Refined Konjai Meal Capsule, twice a day. The control group was given (0.2) g of hexanicotol, three times a day. The course lasted four weeks. The clinical therapy, the effect decreasing of blood lipid and influence on blood lipid of two groups were observed. RESULTS: Compared with the control group, the clinical effect of treatment group is better than the former,(P

Objective To investigate the clinical features, therapy and prognosis of elderly patients with newly diagnosed acute promyelocytic leukemia (APL). Methods The clinical features of 21 elderly patients and 89 patients aged ＜60 with newly diagnosed APL were retrospectively analyzed. Additionally,elderly patients were divided into different groups according to the count of white blood cell (WBC). Results There were no significant differences between elderly patients and patients aged ＜60 in the aspect of sex (male/female: 11/10 vs 47/42), WBC count (high initial WBC: 23.8 % vs 16.9 %), the percentage of bone marrow blasts plus promyelocytes (0.83±0.11 vs 0.83±0.12), complete remission (CR) rate (71.4 % vs 84.3 %),the time of CR occurrence (35.7±10.1 vs 39.1±13.5), the occurrence of retinoic acid syndrome(RAS) (14.3 % vs 22.5 %), disseminated intravascular coagulation (DIC) (52.4 % vs 34.8 %) as well as 2 years overall survival rate (72.7 % vs 80.0 %) (P ＞0.05). Of the 21 elderly patients who received inductive treatment, 5 with high initial WBC and 16 without high initial WBC. The incidences of DIC, early death in high initial WBC group were 80 %, 60 % respectively, which were higher than the group without high initial WBC (43.8 %,18.8 % respectively), whereas CR rate for the group with high initial WBC (40.0 %) was lower than that for the group without high initial WBC (81.3 %). Conclusion Elderly patients with APL could have fine prognosis as well as patients aged ＜60. The results of inductive treatment of elderly patients in high initial WBC group were poor as compared with the group without high initial WBC.

Tu-Jia medicine is an important part of traditional Chinese medicine (TCM).“San-Yuan doctrine”is the guiding ideology of Tu-Jia medicine, but there is no systematic exposition of its literature origin. This paper ar-gued that“San-Yuan doctrine”of Tu-Jia medicine was originated in the“San-Yuan”of Taoism. Its formation was closely related to the impact of Taoism and Tu-Jia culture, the understanding of human physiology and pathology in Tu-Jia medicine. This paper expounded the origin of“San-Yuan doctrine”, the guiding ideology of Tu-Jia medi-cine and Taoism culture through citing a number of theoretical bases. First of all, the concept of“San-Yuan”in Tu-Jia medicine originated in Taoism. Secondly, legends about the Lord Lao-Zi and Medicine King Bodhisattva in Tu-Jia medicine were closely related with Taoism. Moreover, there existed important links between Tu-Jia medicine and Taoist medicine. For example, both of them are aware of the importance of brain. The reason, I think, is firstly due to the penetration of Taoism in Tu-Jia culture. Taoism culture has a profound influence on Tu-Jia culture. Sec-ondly, the understanding of human physiology and disease in Tu-Jia medicine is closely related to“three”. There-fore, Tu-Jia medicine took“San-Yuan doctrine”as its own guiding ideology. It is of great significance to the study of ethnic minority medicine culture and inheriting its academic thoughts by the study of Tu-Jia medicine origin.

Objective To illustrate the clinical relevance of distinct PML-RARα fusion gene isoforms in acute promyelocytic leukemia (APL). Methods The nested reverse transcriptase polymerase chain reaction (RT-PCR) was used to detect the long (L) or short (S) PML-RARα fusion gene isoforms in 92 newly diagnosed APL so as to evaluate the clinical feature, therapeutic reaction and prognosis of the two fusion gene isoforms. Results PML-RARα fusion gene was positive in all 92 APL patients, of which 52(56.5 %) was L type and 40 (43.5 %) was S type. There were no significant differences between L type and S type in the aspect of sex, age, white blood cell count,the percentage of bone marrow blasts plus promyeloeytes and chromosome before treatment. And there were no significant differences between the two isoforms in complete remission (CR) rate, the time of getting CR as well as the occurrence of retinoic acid syndrome (RAS), disseminated intravascular coagulation (DIC), intraeranial hemorrhage. Also, there were no significant differences in overall survival rate (OS) and relapse-free survival rate (RFS) between the two isoforms. Conclusion PML-RARα fusion gene isoforms in APL were not correlated with clinical therapeutic effect or prognosis.

This study successfully established in v itro model of Alzheimerˊs disease ( AD ) in order to investigate effects and mechanisms on AD by Bushen-Huatan-Yizhi Recipe (BSHTYZR, replenishing kidney-essence and removing phlegm to benefit wisdom ) . The PC-12 cells affected by Aβ1-42 incubated were produced for neuron cell model of AD . Then , they were intervened by the serum containing BSHTYZR , which were compared to the serum containing indomethacin . The cell morphology was observed . The neuronal survival was assessed by counting MTT assay . The expression of APP mRNA was detected with RT-PCR . And the protective effect of BSHTYZR on neuronal cells and neurotoxic effects of anti-Aβ was observed . The results showed that 2 . 5 mmol/L Aβ1-42 can significantly decrease the cell viability . The RT-PCR was used on semi-quantitative analysis for expression of APPmRNA. It showed that expression of APP mRNA was increased in each group, and the BSHTYZR group can reduce the expression significantly ( P < 0 . 01 ) . It was concluded that the BSHTYZR method can protect nerve cells , suppress the expression of APP mRNA , and reduce the toxic effects .

Objective To investigate the effect of KIR-HLA receptor-ligand model on the unrelated allo-hematopoietic stem cell transplantation (Allo-HSCT) of acute lymphoblastic leukemia (ALL). Methods The KIR genotype of 23 pairs of ALL patients and their HLA-matched unrelated donors obtained from the Database of China Marrow Donor Program. KIR genotype was determined using PCR-SSP. The expression of inhibitory KIR(iKIR) was determined by flow cytometry analysis on recipients after HSCT. Results Among all 23 donor/recipient pairs, 17 donors with KIR2DL2/L3 could find corresponding HLA-Cw1, 3, 7, 8, 12, 14 ligands in their recipients. Six donors with KIR2DL1 could match with HLA-Cw6, 15 in recipients. Sixteen donors with KIR3DL1 could recognize HLA-Bw4 and 12 donors with 3DL2 could find HLA-AI1 in their corresponding recipients, respectively. Ninteen patients were successfully transplanted, and the death rate of transplantation were 33.3% (2/6)and 40.0% (2/5) in KIR receptor-ligand matched model and the graft versus leukemia(HVG) KIR ligand-mismatching pattern. The frequency of acute graft versus host disease(GVHD) was 50.0% and death rate was 12.5% (1/8) in GVH KIR ligand-mismatching. The incidence rate of activated GVHD(aGVHD) was 20.0% in the HVG KIR ligand-mismatching. Five donor/recipient pairs of KIR gene typing were the KIR-haplotype A, 2 donor/recipient pairs with KIR2DS4 * 001/002 were died, 3 donor/recipient pairs with KIR2DS4 * 003-007 were obtained the disease free survival. The expression of CD158a/2DL1 was low when the patient had no aGVHD, but became much higher when aGVHD occurred. The percentage of NK cell of the patients was decreasing since transplantation, but still higher than normal after HSCT[ (23.4 ± 3.8 ) % vs (2.04 ± 0.58) %, P < 0.05 ]. Conclusion Analysis on KIR-HLA gene loci pattern may provide a useful parameter in predicting the clinical outcome of HLA-matched unrelated allogeneic hematopoietic stem cell transplantation for leukemia patients. Moreover, it may help to increase overall survival and disease free survival after HSCT by preventing the development of GVHD.

OBJECTIVETo investigate the role of different immunoglobulin- like receptor (KIR)haplotypes in haplo- identical hematopoietic stem cell transplantation (HSCT).

METHODKiller cell KIR genotyping was performed on 468 individuals from 156 unrelated families by PCR-SSP. A total of 624 KIR haplotypes from the parents were used for haplotype analysis. Ninety-two patients received haplo-identical HSCT from one of the parents.

RESULTSThe family study showed segregation of one A haplotype and at least 20 unique B haplotypes. The frequency of haplotype A was 72.92% (455/624). The most commonly observed haplotypes in group B were B1, B2, and B3, present at a frequency of 10.26%, 5.77%, and 4.48%, respectively. Compared to KIR gene matched donors (n=17), grafts from KIR gene mismatched donors (n= 14) had a positive effect on survival after haplo- identical HSCT for AML/MDS patients (OS: 88.2%vs 42.9%,P=0.015; RFS: 88.2%vs 35.7%,P=0.007). No effect was observed for ALL/NHL patients (OS: 76.0%vs 75.0%,P=0.727; RFS: 68.0%vs 65.0%,P=0.866). A significantly lower survival rate was observed for transplants from AA (n=52) and AB1/AB2 donors (n=15), compared to other group Bx donors (n=25) (OS: 53.3%vs 96.0%,P=0.017; RFS: 53.3%vs 92.0%,P=0.019). Meanwhile, the risk of relapse was much higher in AA group (n=52) compared to Bx group (n=40) (25.0%vs 5.0%,P=0.009). A higher risk of TRM was observed in AB1/AB2 group (P=0.012). In addition, transplant from donors carried Cen-B was associated with an increased survival compared with Cen-A homozygous donors (OS: 94.7%vs 68.5%,P=0.036; RFS: 89.5%vs 64.4%,P=0.045).

CONCLUSIONOverall, KIR genotyping and haplotype analyses should be useful for selection of the most optimal donors with favorable KIR gene grafts. KIR gene mismatch donors should be preferred for AML/MDS patients. Selecting donors carried Cen- B and avoiding the selection of donors of KIR genotype AA/AB1/AB2 was strongly advisable for haplo-identical HSCT.

Chronic Disease ; Genotype ; Haplotypes ; Hematopoietic Stem Cell Transplantation ; Humans ; Killer Cells, Natural ; Leukemia, Myeloid, Acute ; therapy ; Neoplasm Recurrence, Local ; Receptors, KIR ; genetics ; Survival Rate ; Tissue Donors